Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE - News) today announced that the Company will be presenting at two upcoming investor conferences providing an overview on the Company and its therapeutic programs. The conference information is as follows:

(Logo: http://www.newscom.com/cgi-bin/prnh/20070608/NEF043LOGO )

-- Peter Savas, Chairman and CEO of Alseres Pharmaceuticals, Inc., will present Monday, November 5th at 11:15 am ET at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference, at the New York Palace Hotel in New York.

A live webcast will be available at: http://www.rodmanandrenshaw.com/conferences?id=6&link=confwebcasters

For more information on the conference and speaking companies please go to www.rodmanandrenshaw.com/us07conference

-- Kenneth Rice, Executive Vice President and Chief Financial Officer of Alseres Pharmaceuticals, Inc., will present Thursday, November 8th at 3:20 pm ET at the 9th Annual Massachusetts Biotechnology Council MASS Opportunities Investment Conference, at the Hilton Logan Airport in Boston.

A live webcast will be available, please visit the Investor Relations section of the Alseres website at www.alseres.com

For more information on the conference and speaking companies please go to http://massbio.org/events/mass_opps/index.php

About Alseres Pharmaceuticals, Inc.

Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE - News) is a biotechnology company engaged in developing breakthrough regenerative therapeutics to treat traumatic injuries and degenerative diseases. The Company maintains a world-class intellectual property position in the field of regenerative therapeutics. Our energy and focus is reflected in several important initiatives. Cethrin® is a recombinant-protein-based drug designed to promote nerve repair after acute spinal cord injury. Cethrin has demonstrated positive interim results in a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, Oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Company has a robust molecular imaging development program targeting diagnosis of Parkinson's disease and potentially dementia and ADHD. ALTROPANE®, the lead molecular imaging candidate, is in Phase III clinical trials for the diagnosis of Parkinson's disease. Alseres has research collaborations with Harvard Medical School and Children's Hospital Boston.